Search PubMed⌕ Search

Biomedical subjects

B Silkey

Publications and source records attributed to B Silkey.

6 recordsLinked to original sources
PubMed1999

An outcomes study of an occupational medicine intervention program for the reduction of musculoskeletal disorders and cumulative trauma disorders in the workplace.

Upper-extremity musculoskeletal pains or disorders (MSDs) account for a significant number of work-related illnesses in the US workforce. Although the concept of MSD prevention is appealing, little has been done to demonstrate the successful application and benefit of these programs. In 1995, an aircraft manufacturer established a unique risk-management program based on the individual risk assessment (CtdMAP) for new hires. The MSD intervention program was designed to prospectively evaluate each new employee for their individual risk of developing MSDs in the workplace. Before job placement, individuals at higher risk were assigned to a period of transitional work. Workers' compensation costs decreases per year were 16%, 3%, 24%, and 12%, while work hours increased by 56%. Employer-estimated savings in direct workers' compensation costs per year were $469,990, $678,337, $1,936,105, and $1,995,759.

Algorithms↗
PubMed1994

Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder.

The goal of this paper is to increase the psychiatrist's awareness of issues and methods in pharmacoeconomics with the hope that this will lead to greater physician involvement in the ongoing cost-management debates. This paper will first examine the underlying dynamics of health economics as they relate to the treatment of major depressive disorder. It will then discuss cost-benefit factors in antidepressant pharmacotherapy with special focus on the economic implications of clinically relevant differences among antidepressant drug classes. The paper ends with a review of methods for the economic analysis of drug therapies and a discussion of research needs in this area.

Adult↗
PubMedDate not supplied

A pharmacoeconomic model to evaluate antibiotic costs.

STUDY OBJECTIVES: To characterize patient sociodemographics and health, describe vancomycin treatment parameters and clinician-rated outcomes, and determine costs associated with treatment including preparation and administration, adverse events, and toxicity. DESIGN: A prospective study to develop a model for costs associated with antibiotic treatment (vancomycin). SETTING: A community hospital. PATIENTS: One hundred adults with active infections. INTERVENTIONS: Mean duration of therapy was 10 days, and most patients received 2000 mg/day. Serum concentrations were monitored in two of three patients. Detailed cost analyses were completed on a subset of 26 patients selected at random from the overall sample. MEASUREMENTS AND MAIN RESULTS: Sepsis and skin and skin structure infections were the most common indications for vancomycin therapy. Treatment was effective in 81 patients, failed in 9, and was not evaluable in 10. Thirty-eight percent of patients experienced adverse events attributable to the drug. Phlebitis was common, and red man syndrome, nephrotoxicity, and ototoxicity were infrequent. CONCLUSIONS: Total cost of vancomycin treatment for 100 patients was $30,251: $23,855 for preparation and administration, $1710 for monitoring serum concentrations, and $4686 for treating adverse reactions. Drug costs accounted for only 55% of the total cost. Vancomycin is safe and effective, but phlebitis is underreported and significantly affects cost.

Adult↗